The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

EBMT 2018 | Comparison of safety outcomes between PTCy-based haploidentical and HLA-matched related or unrelated donor transplantation for patients with R/R aggressive NHL

Mar 26, 2018

An oral session on lymphoma took place at the 44 thEuropean Society for Blood and Marrow Transplantation(EBMT) annual meeting on 19 March 2018. Abstract OS1-2was presented by Sarah Haebe, from the Department of Medicine III, Laboratory for Experimental Leukemia and Lymphoma Research, Ludwig-Maximilians University, Munich, Germany which compared the safety and efficacy of post-transplantation cyclophosphamide (PTCy)-based haploidentical donor (haplo-D) transplantation versus HLA-matched related donor (MRD) or unrelated donor (URD) transplantation in refractory or relapsed (R/R) aggressive non-Hodgkin lymphoma (aNHL).

In this study, patients treated with T-cell replete (TCR) HLA-haploidentical hematopoietic stem cell transplantation (haplo-HSCT) were matched-paired with patients receiving HLA-matched transplantation (MRD and URD). The age (± 5 years) and the stage at HSCT (defined as complete response [CR] or non-CR) varied between pair-matched patients in this analysis. The primary endpoints of this study were overall survival (OS), progression-free survival (PFS), non-relapse mortality (NRM) and graft-versus-host disease (GvHD) incidence.

Demographics

  • N = 21 patients in each group (TCR/PTCy haplo-HSCT, MRD and URD)
  • Successful match-pair single center analysis of 21 haplo-HSCT with 21 MRD and 21 URD patients
  • Median age of all patients (range): 48 (20–65)
  • Histology (all patients):
    • Aggressive NHL: 62%
    • Indolent NHL: 22%
    • T-cell NHL (T-NHL): 16%
  • Median number of prior therapies (range): 4 (2–6)
  • Conditioning regimen (all patients):
    • Reduced intensity conditioning (RIC): 58%
    • Non-myeloablative conditioning(NMA): 21%
    • Myeloablative conditioning (MAC): 21%

Key Findings

  • Median follow-up: 39 months
  • CR at Day +30 (all patients) = 84%;
  • Median time to engraftment (days; P= 0.2):
    • MRD = 16
    • URD = 18
    • Haplo = 20
  • PFS and OS at 2-years (%):
    • MRD = 33 and 43
    • URD = 19 and 38
    • Haplo = 43 and 52
  • PFS and OS at 3-years (%):
    • MRD = 29 and 33
    • URD = 19 and 38
    • Haplo = 38 and 52
  • Occurrence of acute GvHD II–IV at 100-days follow-up (%; P= 0.03):
    • MRD = 30
    • URD = 55
    • Haplo = 21
  • Occurrence of chronic GvHD (moderate and severe) at one year follow-up (%; P= 0.4):
    • MRD = 39
    • URD = 35
    • Haplo = 20
  • Non-relapse mortality (NRM) within one year after transplantation (%):
    • MRD = 2
    • URD = 33
    • Haplo = 24
  • Relapse rate within the first year after transplantation (%):
    • MRD = 29
    • URD = 38
    • Haplo = 24
  • Death from aplasia = 6 patients

The results from this study demonstrated similar outcomes between patients treated with haplo-HSCT using PTCy and patients who received HLA-matched transplantation. With a higher incidence of acute GvHD and NRM rates after URD transplantation, the authors suggested that haplo-HSCT might be used as an efficient safer alternative regimen for patients with aNHL.

  1. Sarah Haebe et al.T-cell replete HLA-haploidentical transplantation using PTCy versus HLA-matched related/unrelated donor transplantation in refractory or relapsed aggressive NHL- Results of a single center matched-pair analysis. Oral abstract OS1-2. EBMT 44th Annual Meeting, Lisbon, Portugal.